HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

efgartigimod alfa

Also Known As:

ARGX-113; Vyvgart

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Heo, Young-A: 1 article (02/2022)

Related Diseases

1.	Myasthenia Gravis 05/01/2023 - "Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use." 01/01/2023 - "Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use." 02/01/2022 - "Efgartigimod (efgartigimod alfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. " 01/01/2022 - "Efgartigimod alfa (Vyvgart) for myasthenia gravis." 01/01/2023 - "Intravenous efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA; Vyvgart®) is the first neonatal Fc receptor antagonist approved in several countries worldwide, including the USA and EU for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive, and in Japan for the treatment of gMG regardless of antibody status. "
2.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/01/2023 - "Efgartigimod alfa for the treatment of primary immune thrombocytopenia."
3.	Autoimmune Diseases (Autoimmune Disease) 02/01/2022 - "Efgartigimod (efgartigimod alfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. "

Related Drugs and Biologics

1.	neonatal Fc receptor
2.	efgartigimod alfa
3.	Cholinergic Receptors
4.	glucose-mannose-glucose